Effect of ipragliflozin on liver gene expression in HFD-fed WT mice. Chikara Komiya Kyoichiro Tsuchiya Kumiko Shiba Yasutaka Miyachi Shunsaku Furuke Noriko Shimazu Shinobu Yamaguchi Kazuo Kanno Yoshihiro Ogawa 10.1371/journal.pone.0151511.g002 https://plos.figshare.com/articles/figure/Effect_of_ipragliflozin_on_liver_gene_expression_in_HFD-fed_WT_mice_/3961263 <p>Gene expression levels in the liver associated with (A) lipogenesis, β-oxidation, gluconeogenesis, and (B) inflammation after 4 weeks of the vehicle or ipragliflozin treatment. # <i>p</i> < 0.05, ## <i>p</i> < 0.01 vs SD/Veh; * <i>p</i> < 0.05, ** <i>p</i> < 0.01 vs HFD/Veh. <i>n</i> = 6–8.</p> 2016-03-15 00:23:02 epididymal Type 2 Diabetic Patients Irrespective ipragliflozin ameliorates obesity-associated inflammation T 2DM hepatic steatosis accumulation SGLT 2 inhibitors attenuating body weight reduction Body Weight Reduction Type 2 diabetes mellitus insulin resistance body weight SGLT 2 inhibitor ipragliflozin NAFLD increase energy intake T 2DM body weight reduction Sodium-glucose cotransporter 2